Pam Belluck's article follows Amanda Sifford, a 58-year-old A.L.S. patient, who experiences a significant improvement in her condition after receiving tofersen, a newly approved therapy targeting a specific genetic mutation, despite battling severe side effects and the ongoing challenges of the disease, offering hope for a treatable future for A.L.S. patients. #ALS #GeneticTherapy #Neurology #US #CA #BG
www.nytimes.com
Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Some
Pam Belluck spent time with an A. L. S. patient who is being treated with the new therapy in Miami.
Time was running out for Amanda Sifford, she and her doctors could tell.